Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) EPS (Basic): 2020-2025

Historic EPS (Basic) for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to $0.13.

  • Pharming Group N.V's EPS (Basic) rose 6730.52% to $0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.15, marking a year-over-year increase of 422.78%. This contributed to the annual value of -$0.02 for FY2024, which is 12.50% down from last year.
  • According to the latest figures from Q3 2025, Pharming Group N.V's EPS (Basic) is $0.13, which was up 856.29% from $0.01 recorded in Q2 2025.
  • Pharming Group N.V's EPS (Basic)'s 5-year high stood at $15.68 during Q1 2021, with a 5-year trough of -$15.63 in Q2 2021.
  • Over the past 3 years, Pharming Group N.V's median EPS (Basic) value was -$0.00 (recorded in 2023), while the average stood at $0.01.
  • As far as peak fluctuations go, Pharming Group N.V's EPS (Basic) crashed by 833.33% in 2022, and later surged by 6,730.52% in 2025.
  • Quarterly analysis of 5 years shows Pharming Group N.V's EPS (Basic) stood at $0.00 in 2021, then tumbled by 833.33% to -$0.02 in 2022, then soared by 77.27% to -$0.01 in 2023, then soared by 180.00% to $0.00 in 2024, then soared by 6,730.52% to $0.13 in 2025.
  • Its last three reported values are $0.13 in Q3 2025, $0.01 for Q2 2025, and $0.00 during Q4 2024.